Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The purpose of this article is to describe dependence and withdrawal phenomena related to CNS drugs discontinuation and to clarify issues related to the evaluation of clinical drug withdrawal and rebound as they relate to safety in new drug development. The article presents current understanding and definitions of drug dependence and withdrawal which are also relevant and important features of addiction, though not the same. Addiction, called substance use disorder in DSM-5, affects an individual’s brain and behaviour, represents uncontrollable drug abuse and inability to stop taking a drug regardless of the harm it causes. Characteristic withdrawal syndromes following abrupt discontinuation of CNS-active drugs from numerous drug classes are described. These include drugs both scheduled and non-scheduled in the Controlled Substances Act, which categorizes drugs in five schedules based on their relative abuse potentials and dependence liabilities and for regulatory purposes. Schedules 1 and 2 contain drugs identified as those with the highest abuse potential and strictest regulations. Less recognized aspects of drug withdrawal, such as rebound and protracted withdrawal syndromes for several drug classes are also addressed. Part I presents relevant definitions and describes clinical withdrawal and dependence phenomena. Part II reviews known withdrawal syndromes for the different drug classes, Part III describes rebound and Part IV describes protracted withdrawal syndromes. To our knowledge, this is the first compilation of withdrawal syndromes for CNS drugs. Part V provides details of evaluation of dependence and withdrawal in the clinical trials for CNS drugs, which includes general design recommendations, and several tools, such as withdrawal questionnaires and multiple scales that are helpful in the systematic evaluation of withdrawal. The limitations of different aspects of this method of dependence and withdrawal evaluation are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About half of the patients on antidepressants who try to discontinue or reduce the dose experience withdrawal symptoms”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In basic pharmacology and addiction medicine, these neurophysiological adaptations are typically defined as physical dependence (no to be confused with addiction) and a withdrawal syndrome upon dose reduction or treatment discontinuation is its sole clinical manifestation (Horowitz et al., 2023; Horowitz and Taylor, 2023; Lerner and Klein, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lerner and Klein, 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This process of re-setting of neurons and networks has been estimated to take between hours and years (although research is lacking in this area).20,21”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence suggests that physiological adaptations to opioid dependence might take months or years to resolve.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [21]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
Barkley, R. A., & Poillion, M. J. (1994) · Behavioral Disorders · doi:10.1177/019874299401900205 · Cited by 4,639
Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
SPRAFKIN, J., & CARLSON, G. A. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1266 · Cited by 1,900
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,731
Addiction and the brain antireward system
Koob, G. F., & Le Moal, M. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093548 · Cited by 1,457
Rosen's emergency medicine : concepts and clinical practice.
Marx, J. A. (2017) · Cited by 1,258
Rosenʼs emergency medicine: concepts and clinical practice
Rotheray, K. R., & Cattermole, G. N. (2010) · European Journal of Emergency Medicine · doi:10.1097/mej.0b013e32833728f4 · Cited by 1,120
Hudak, M. L., Tan, R. C., THE COMMITTEE ON DRUGS, THE COMMITTEE ON FETUS AND NEWBORN, Frattarelli, D. A. C., Galinkin, J. L., Green, T. P., Neville, K. A., Paul, I. M., Van Den Anker, J. N., et al. (2012) · Pediatrics · doi:10.1542/peds.2011-3212 · Cited by 877
Effects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“Tobacco/nicotine withdrawal usually begins within 24– 72 h of stopping or decreasing tobacco use, peaks at 2– 3 days after abstinence, and lasts 2–4 weeks (Hughes, 2007; New South Wales Government, 2008; APA, 2013; Jackson et al., 2015) and label Nicotrol 2010, Table 1.”
BackgroundSubstance Abuse and Mental Health Services Administration
(2009) · Encyclopedia of Substance Abuse Prevention, Treatment, & Recovery · doi:10.4135/9781412964500.n301 · Cited by 720
Neurobiological mechanisms for opponent motivational processes in addiction
Koob, G. F., & Le Moal, M. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0094 · Cited by 702
Kocherlakota, P. (2014) · Pediatrics · doi:10.1542/peds.2013-3524 · Cited by 612
Two New Rating Scales for Opiate Withdrawal
Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998709001515 · Cited by 599
Neuroleptic Malignant Syndrome
Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.870 · Cited by 579
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Benzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 534
Review of the Validity and Significance of Cannabis Withdrawal Syndrome
Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1967 · Cited by 522
Tintinalli's Emergency Medicine: A Comprehensive Study Guide
Tintinalli, J. E., Chief, Stapczynski, J. S., John, O. P., Yealy, D. M., Meckler, G. D., & Cline, D. M. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 521
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 9×
“These in- clude drugs both scheduled and non-scheduled in the Controlled Substances Act, which categorizes drugs in five schedules based on their relative abuse potentials and dependence liabilities and for regulatory purposes.”
BackgroundInfluentialEffects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant
Iqbal, M. M., Sobhan, T., & Ryals, T. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.1.39 · Cited by 427 · cited 1×
“Use of BZ during the later stages of pregnancy can result in withdrawal symptoms in the neonate such as apnoea, bradycardia, hypertonia, irritability, hypothermia, hyperactivity, tachypnoea, restlessness, tremors, hyperreflexia, inconsolable crying, cyanosis, diarrhoea, vomiting and feeding difficulties (Iqbal et al.,…”
Kariisa, M., Scholl, L., Wilson, N., Seth, P., & Hoots, B. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6817a3 · Cited by 400
Sanz, E. J., De-las-Cuevas, C., Kiuru, A., Bate, A., & Edwards, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17865-9 · Cited by 382
Dextroamphetamine: Cognitive and Behavioral Effects in Normal Prepubertal Boys
Rapoport, J. L., Buchsbaum, M. S., Zahn, T. P., Weingartner, H., Ludlow, C., & Mikkelsen, E. J. (1978) · Science · doi:10.1126/science.341313 · Cited by 373 · cited 1×
“Stimulants such as methylphenidate and amphetamine may cause rebound in children with attention-deficit/ hyperactivity disorder, which can include serious and consistent deterioration of behaviour manifested in sadness, crying, emotional lability, irritability, social withdrawal, restlessness, distractibility, bellige…”
BackgroundThe cannabis withdrawal syndrome
Budney, A. J., & Hughes, J. R. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218592.00689.e5 · Cited by 349
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Rabinak, C. A., & Nirenberg, M. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.294 · Cited by 349
Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users
Cuttler, C., Mischley, L. K., & Sexton, M. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0010 · Cited by 349
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder
Nutt, D. J., & Malizia, A. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.5.390 · Cited by 339
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children
Anand, K. J. S., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J., Carcillo, J., Newth, C. J. L., Prodhan, P., Dean, J. M., et al. (2010) · Pediatrics · doi:10.1542/peds.2009-0489 · Cited by 321
Psychoactive drug abuse in older adults
Simoni-Wastila, L., & Yang, H. K. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.10.002 · Cited by 306
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301
(2004) · PubMed · Cited by 296
An analysis of the root causes for opioid-related overdose deaths in the United States
Webster, L. R., Cochella, S., Dasgupta, N., Fakata, K. L., Fine, P. G., Fishman, S. M., Grey, T., Johnson, E. M., Lee, L. K., Passik, S. D., et al. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01134.x · Cited by 295
Anabolic–androgenic steroid dependence: an emerging disorder
Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I., & Pope Jr, H. G. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02734.x · Cited by 294
The ASAM principles of addiction medicine
Ries, R. K., Fiellin, D. A., Miller, S. C., & Saitz, R. (2014) · Wolters Kluwer Health eBooks · Cited by 290
Benzodiazepine Dependence A Review of the Evidence
Owen, R. T., & Tyrer, P. (1983) · Drugs · doi:10.2165/00003495-198325040-00003 · Cited by 287
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Back, S. E., Payne, R. L., Wahlquist, A. H., Carter, R. E., Stroud, Z., Haynes, L., Hillhouse, M., Brady, K. T., & Ling, W. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.596982 · Cited by 277
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · cited 10×
“Symptoms may appear 36–96 h or later after drug discontinuation, dose reduction or switch, depending on the drug’s duration of action and last up to 6 weeks (Chouinard et al., 2017).”
BackgroundInfluentialMartin, W. R., & Jasinski, D. R. (1969) · Journal of Psychiatric Research · doi:10.1016/0022-3956(69)90007-7 · Cited by 259
The benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246 · cited 5×
“…vomiting, vertigo, cramps, weakness, tremor, tachycardia, postural hypotension, hyperthermia, panic attacks, depression, psychotic reactions, depersonalization, derealization, delirium, delusions and hallucinations (MacKinnon and Parker, 1982; Petursson, 1994; New South Wales Government, 2008).”
BackgroundInfluentialThe cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
Riccio, C. A., Waldrop, J. J. M., Reynolds, C. R., & Lowe, P. (2001) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.13.3.326 · Cited by 218
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Hatcher, S. E., Waubant, E., Nourbakhsh, B., Crabtree-Hartman, E., & Graves, J. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0826 · Cited by 217
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 3×
“Serious withdrawal reactions may be present, such as tachycardia, cyanosis and convulsions (Cowe et al., 1982; Bloem et al., 1999; Haddad, 2001; Hudak et al., 2012; ter Horst et al., 2012) and label Anafranil (2014).”
BackgroundEvidence from opiate binding studies that heroin acts through its metabolites
Inturrisi, C. E., Schultz, M., Shin, S., Umans, J. G., Angel, L., & Simon, E. J. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90616-1 · Cited by 212
Pecknold, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290043006 · Cited by 204
Victorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201
Rebound Insomnia: A New Clinical Syndrome
Kales, A., Scharf, M. B., & Kales, J. D. (1978) · Science · doi:10.1126/science.684426 · Cited by 200
Rebound Insomnia and Rebound Anxiety: A Review
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000137794 · Cited by 198
A Neuroleptic Malignantlike Syndrome due to Levodopa Therapy Withdrawal
Friedman, J. H. (1985) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1985.03360190098033 · Cited by 193
Rook, E., Huitema, A., Brink, W., Ree, J., & Beijnen, J. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406775268219 · Cited by 189
Cowen, P. J., & Nutt, D. J. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90550-5 · Cited by 181
Anabolic steroid abuse and dependence
Brower, K. J. (2002) · Current Psychiatry Reports · doi:10.1007/s11920-002-0086-6 · Cited by 181
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 4×
“…depression, psychotic reactions, memory impairment, motor symptoms (muscle jerking, blepharospasm), paraesthesia, formication, tinnitus and irritable bowel syndrome, and there is a characteristic fluctuation of symptoms that may wax and wane (Smith and Wesson, 1983; Ashton, 1991; SAMHSA, 2010).”
BackgroundMethodInfluentialChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164 · cited 14×
“These include: anxiety, panic, agitation, insomnia, depression, obsessions and compulsions (Bhanji et al., 2006; Chouinard and Chouinard, 2015).”
BackgroundInfluentialThe Parkinsonism-Hyperpyrexia Syndrome
Newman, E. J., Grosset, D. G., & Kennedy, P. G. E. (2008) · Neurocritical Care · doi:10.1007/s12028-008-9125-4 · Cited by 162
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Should protracted withdrawal from drugs be included in DSM-IV?
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.695 · Cited by 158
Underlying Factors in Drug Overdose Deaths
Dowell, D., Noonan, R. K., & Houry, D. (2017) · JAMA · doi:10.1001/jama.2017.15971 · Cited by 158
Margolese, H. C., Chouinard, G., Kolivakis, T., Beauclair, L., & Miller, R. J. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000907 · Cited by 157
Maternal barbiturate utilization and neonatal withdrawal symptomatology
Desmond, M. M., Schwanecke, R. P., Wilson, G. S., Yasunaga, S., & Burgdorff, I. (1972) · The Journal of Pediatrics · doi:10.1016/s0022-3476(72)80577-8 · Cited by 156
Soldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199909000-00004 · Cited by 154
(1997) · PubMed · Cited by 149
Ista, E., van Dijk, M., Gamel, C. J., Tibboel, D., & de Hoog, M. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318181600d · Cited by 145
Sørensen, P. S., Koch‐Henriksen, N., Petersen, T., Ravnborg, M. H., Oturai, A. B., & Sellebjerg, F. T. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7325-8 · Cited by 143
Anabolic Androgenic Steroids and Suicide
Thiblin, I., Runeson, B., & Rajs, J. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022313529794 · Cited by 141
Pain Assessment and Pharmacologic Management
Pasero, C., & McCaffery, M. (2010) · Medical Entomology and Zoology · Cited by 139
The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence
Jansen, K. L. R., & Darracot-Cankovic, R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400480 · Cited by 137
A Naturalistic Assessment of the Motor Activity of Hyperactive Boys: II. Stimulant Drug Effects
Porrino, L. J. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010098013 · Cited by 128 · cited 1×
“Stimulants such as methylphenidate and amphetamine may cause rebound in children with attention-deficit/ hyperactivity disorder, which can include serious and consistent deterioration of behaviour manifested in sadness, crying, emotional lability, irritability, social withdrawal, restlessness, distractibility, bellige…”
BackgroundSex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.
Herrmann, E. S., Weerts, E. M., & Vandrey, R. G. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000053 · Cited by 127
New mechanisms and perspectives in nicotine withdrawal
Jackson, K. J., Muldoon, P. P., Biasi, M. D., & Damaj, M. I. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.009 · Cited by 125
[Neuroleptic malignant syndrome].
Gázquez, J. M. C. D. L. B., Montero‐Pérez, F. J., Sánchez Medina, C., & Murillo, L. M. J. (1992) · PubMed · Cited by 124
Diagnostic criteria for cannabis withdrawal syndrome
Gorelick, D. A., Levin, K. H., Copersino, M. L., Heishman, S. J., Liu, F., Boggs, D. L., & Kelly, D. L. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.11.007 · Cited by 121
Gender-linked differences in the expression of physical dependence in the rat
Cicero, T. J., Nock, B. L., & Meyer, E. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00740-2 · Cited by 114
Benzodiazepines and withdrawal psychosis. Report of three cases
Preskorn, S. (1977) · JAMA · doi:10.1001/jama.237.1.36 · Cited by 112
Controlled discontinuation of benzodiazepine treatment for patients with panic disorder
Noyes, R., Garvey, M. J., Cook, B. L., & Suelzer, M. T. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.4.517 · Cited by 111
Neonatal paroxetine withdrawal syndrome
Stiskal, J. A., Kulin, N., Koren, G., Ho, T., & Ito, S. (2001) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/fn.84.2.f134 · Cited by 110
Problems and Pitfalls in the Use of Benzodiazepines in the Elderly
Kruse, W. (1990) · Drug Safety · doi:10.2165/00002018-199005050-00003 · Cited by 110
The treatment of benzodiazepine dependence
ASHTON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03755.x · Cited by 110
Valuck, R. J., Orton, H. D., & Libby, A. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04943 · Cited by 106 · cited 3×
“Withdrawal of antidepressants and other CNS drugs such as BZ and stimulants may lead to dangerous, even lifethreatening, withdrawal symptoms and lead to significant public health concerns, such as suicidality (Risse et al., 1990; Valuck et al., 2009; APA, 2013; Fava et al., 2015).”
BackgroundCholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104 · cited 1×
“For these drugs, the common withdrawal symptoms are nausea, vomiting, diarrhoea, anorexia, influenza-like syndrome, rhinorrhoea, diaphoresis, myalgia, paraesthesia, anxiety, agitation, restlessness, insomnia, vertigo and tremor (Dilsaver, 1994; Borison, 1996; Shiovitz et al., 1996) and labels e.”
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Malignant syndrome in Parkinson's disease: concept and review of the literature
Mizuno, Y., Takubo, H., Mizuta, E., & Kuno, S. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00125-6 · Cited by 102
Fatal hyperpyrexia after withdrawal of levodopa
Sechi, G., Tanda, F., & Mutani, R. (1984) · Neurology · doi:10.1212/wnl.34.2.249 · Cited by 102
Cannabis Withdrawal: a Review of Neurobiological Mechanisms and Sex Differences
Schlienz, N. J., Budney, A. J., Lee, D. C., & Vandrey, R. G. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0143-1 · Cited by 101
Ketamine associated psychedelic effects and dependence.
Dk, L. (2003) · PubMed · Cited by 100
Benzodiazepine Dependency Syndromes
Smith, D. E., & Wesson, D. R. (1983) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1983.10472127 · Cited by 90
Catatonia After Benzodiazepine Withdrawal
Rosebush, P. I., & Mazurek, M. F. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00007 · Cited by 89
Benzodiazepine Withdrawal Syndrome: A Literature Review and Evaluation
Mackinnon, G. L., & Parker, W. A. (1982) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998209002608 · Cited by 87
Gender differences in subjective discontinuation symptoms associated with ketamine use
Chen, W.-Y., Huang, M.-C., & Lin, S.-K. (2014) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-9-39 · Cited by 87 · cited 2×
“There are limited human data available regarding difference in severity of withdrawal symptoms by sex; some studies discuss this topic for different pharmacological groups (Agrawal et al., 2008; Copersino et al., 2010; Chen et al., 2014; Chartier et al., 2015; Herrmann et al., 2015; Cuttler et al., 2016; Rungnirundorn…”
BackgroundPal, H. R., Berry, N., Kumar, R., & Ray, R. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000323 · Cited by 87 · cited 1×
“Ketamine is known for the formation of severe psychological dependence and significant, rapidly developing tolerance (Kamaya and Krishna, 1987; Hurt and Ritchie, 1994; Jansen and Darracot-Cankovic, 2001; Pal et al., 2002) without a prominent physical withdrawal syndrome.”
BackgroundOda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 84
Drug discontinuation effects are part of the pharmacology of a drug
Reidenberg, M. M. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183285 · Cited by 82
Kan, C. C., Hilberink, S. R., & Breteler, M. H. M. (2004) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2003.12.007 · Cited by 81
A case of ketamine dependence with discontinuation symptoms
Critchlow, D. G. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01494.x · Cited by 79
Acute Benzodiazepine Withdrawal Syndrome After Midazolam Infusions in Children
Sury, M. R. J., Billingham, I., Russell, G. N., Hopkins, C. S., Thornington, R. E., & VIVORI, E. (1989) · Critical Care Medicine · doi:10.1097/00003246-198903000-00027 · Cited by 78
Seizure following sudden zolpidem withdrawal
Cubała, W. J., & Landowski, J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.009 · Cited by 77
Stimulant Rebound: How Common Is It and What Does It Mean?
Carlson, G. A., & Kelly, K. L. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322163853 · Cited by 76
Torres, O. V., Gentil, L. G., Natividad, L. A., Carcoba, L. M., & O’Dell, L. E. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00038 · Cited by 76
Sociodemographic Characteristics of Cannabis Smokers and the Experience of Cannabis Withdrawal
Copersino, M. L., Boyd, S. J., Tashkin, D. P., Huestis, M. A., Heishman, S. J., Dermand, J. C., Simmons, M. S., & Gorelick, D. A. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.503825 · Cited by 75
Abuse, Dependence, and Epileptic Seizures after Zolpidem Withdrawal[colon] Review and Case Report
Aragona, M. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200009000-00008 · Cited by 75
Antidepressants and suicidal behaviour in unipolar depression
Yerevanian, B. I., Koek, R. J., Feusner, J. D., Hwang, S., & Mintz, J. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00437.x · Cited by 75
An update on zolpidem abuse and dependence
Victorri-Vigneau, C., Gérardin, M., Rousselet, M., Guerlais, M., Grall-Bronnec, M., & Jolliet, P. (2014) · Journal of Addictive Diseases · doi:10.1080/10550887.2014.882725 · Cited by 74
Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety
Harte-Hargrove, L. C., & Dow-Edwards, D. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.048 · Cited by 73
Risse, S. C., Whitters, A. C., Burke, J., Chen, S., Scurfield, R. M., & Raskind, M. A. (1990) · PubMed · Cited by 72
Neonatal convulsions caused by withdrawal from maternal clomipramine.
Cowe, L., Lloyd, D. J., & Dawling, S. (1982) · BMJ · doi:10.1136/bmj.284.6332.1837-a · Cited by 71
Zopiclone: is it a pharmacologic agent for abuse?
Cimolai, N. (2007) · PubMed Central · Cited by 69
Women and the Experience of Pain and Opioid Use Disorder: A Literature-based Commentary
Koons, A. L., Greenberg, M. R., Cannon, R. D., & Beauchamp, G. A. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.12.016 · Cited by 68
Overdose Deaths Involving Fentanyl and Fentanyl Analogs — New York City, 2000–2017
Colon-Berezin, C., Nolan, M. L., Blachman-Forshay, J., & Paone, D. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6802a3 · Cited by 68
Serrano‐Dueñas, M. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00035-4 · Cited by 64
Larochelle, C., Metz, I., Lécuyer, M., Terouz, S., Roger, M., Arbour, N., Brück, W., & Prat, A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516641775 · Cited by 64
Quazepam and flurazepam: Long-term use and extended withdrawal
Kales, A., Bixler, E. O., Soldatos, C. R., Vela-Bueno, A., Jacoby, J., & Kales, J. D. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.236 · Cited by 62
DIAZEPAM IN NEWLY ADMITTED SCHIZOPHRENICS.
Hollister, L. E., Jl, B., Kimbell, I., SAVAGE, C., & Overall, J. E. (1963) · PubMed · Cited by 62
Faulkner, P., Petersen, N., Ghahremani, D. G., Cox, C. M., Tyndale, R. F., Hellemann, G., & London, E. D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4755-x · Cited by 62
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
The nature of the discontinuation syndrome associated with antidepressant drugs.
Shelton, R. C. (2006) · PubMed · Cited by 60
Withdrawal phenomena associated with antidepressant and antipsychotic agents
Dilsaver, S. C. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00002 · Cited by 60
Agrawal, A., Pergadia, M. L., & Lynskey, M. T. (2008) · The American Journal on Addictions · doi:10.1080/10550490802019519 · Cited by 59
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment
Спивак, Б., Weizman, A., Wolovik, L., Hermesh, H., Tyano, S., & Munitz, H. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb06473.x · Cited by 59
Clozapine withdrawal rebound psychosis.
Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56
Himei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56
Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study
Voshaar, R. C. O., van Balkom, A. J. L. M., & Zitman, F. G. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.09.007 · Cited by 55
Bobzean, S. A. M., Kokane, S. S., Butler, B. D., & Perrotti, L. I. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.057 · Cited by 55
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment
Faissner, S., Hoepner, R., Lukas, C., Chan, A., Gold, R., & Ellrichmann, G. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615594575 · Cited by 53
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 53
Evaluation of sex differences in cannabinoid dependence
Marusich, J. A., Lefever, T. W., Antonazzo, K. R., Craft, R. M., & Wiley, J. L. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.01.019 · Cited by 51
Anabolic Steroid Abuse and Dependence in Clinical Practice
Brower, K. J. (2009) · The Physician and Sportsmedicine · doi:10.3810/psm.2009.12.1751 · Cited by 49
Tricyclic Antidepressant Withdrawal Syndrome
Garner, E. M., Kelly, M. W., & Thompson, D. F. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700912 · Cited by 49
Rebound Insomnia and Elimination Half‐Life: Assessment of Individual Subject Response
Bixler, E. O., Kales, J. D., Kales, A., Jacoby, J. A., & Soldatos, C. R. (1985) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1985.tb02811.x · Cited by 49
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.779a · Cited by 49
Midazolam: Dose-Response Studies of Effectiveness and Rebound Insomnia
Kales, A., Soldatos, C. R., Bixler, E. O., Goff, P. J., & Vela-Bueno, A. (1983) · Pharmacology · doi:10.1159/000137795 · Cited by 48
KAMAYA, H., & KRISHNA, P. R. (1987) · Anesthesiology · doi:10.1097/00000542-198711000-00054 · Cited by 48
Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs.
Crane, G. E. (1968) · PubMed · Cited by 47
Alprazolam: Effects on Sleep and Withdrawal Phenomena
Kales, A., Bixler, E. O., Vela‐Bueno, A., Soldatos, C. R., & Manfredi, R. L. (1987) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1987.tb03058.x · Cited by 46
Roy‐Byrne, P., Dager, S. R., Cowley, D. S., VITALIANO, P. P., & Dl, D. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.7.860 · Cited by 46
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45
Spadotto, V., Zorzi, A., ElMaghawry, M., Meggiolaro, M., & Pittoni, G. M. (2013) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872612474923 · Cited by 45
Anand, K. J. S., & Ingraham, J. W. (1996) · Critical Care Nurse · doi:10.4037/ccn1996.16.6.87 · Cited by 44
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362317 · Cited by 44
Lorazepam—Efficacy, side effects, and rebound phenomena
Scharf, M. B., & Jacoby, J. A. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.27 · Cited by 43 · cited 1×
“Rebound anxiety or panic attacks resulted from abrupt withdrawal of BZ such as alprazolam, lorazepam, diazepam, clorazepate and bromazepam (Scharf et al., 1982; Fontaine et al., 1984; Pecknold et al., 1988; Rickels et al., 1988; Roy-Byrne et al., 1989; Chouinard, 2004).”
BackgroundCatastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
González‐Suarez, I., de Antonio, L. R., Orvíz, A., Moreno‐García, S., Valle‐Arcos, M. D., Matías‐Guiu, J. A., Valencia, C., Jorquera, M., & Oreja‐Guevara, C. (2017) · Brain and Behavior · doi:10.1002/brb3.671 · Cited by 43
Neuroleptic malignant syndrome after neuroleptic discontinuation
Amore, M., & Zazzeri, N. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00269-3 · Cited by 42 · cited 1×
“, 2007), to antipsychotic withdrawal is a neuroleptic malignant syndrome (NMS), characterized by hyperthermia, muscular rigidity, rhabdomyolysis, autonomic instability, mental status changes, diaphoresis, incontinence and elevated creatine phosphokinase (Corrigan and Coulter, 1988; Kasckow et al., 1990; Spivak et al.,…”
BackgroundLIGHT, A. B. (1929) · Archives of Internal Medicine · doi:10.1001/archinte.1929.00140010004001 · Cited by 42
Discontinuation reactions following sertraline
Leiter, F. L., Nierenberg, A. A., Sanders, K. M., & Stern, T. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00311-8 · Cited by 40 · cited 1×
“The SSRIs and SNRIs withdrawal syndrome is characterized by the following symptoms, general: headaches, flu-like symptoms, tachycardia; gastrointestinal: nausea, vomiting, diarrhoea, anorexia; sleep-related: vivid dreams, nightmares, insomnia or hypersomnia; neuropsychiatric: anxiety, depression, suicidality, hypomani…”
Background“Broken Heart Syndrome” After Separation (From OxyContin)
Rivera, J., Locketz, A. J., Fritz, K. D., Horlocker, T. T., Lewallen, D. G., Prasad, A., Bresnahan, J. F., & Kinney, M. A. O. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.825 · Cited by 38
Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena
Dilsaver, S. C. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90097-z · Cited by 38
Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center
Rungnirundorn, T., Verachai, V., Gelernter, J., Malison, R. T., & Kalayasiri, R. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000262 · Cited by 37
Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure.
Sethi, P. K., & Khandelwal, D. C. (2005) · PubMed · Cited by 36
DEATH DUE TO WITHDRAWAL OF BARBITURATES
Fraser, H. F., Shaver, M. P., Maxwell, E., & Isbell, H. (1953) · Annals of Internal Medicine · doi:10.7326/0003-4819-38-6-1319 · Cited by 36
Opioid withdrawal signs and symptoms in children: Frequency and determinants
Fisher, D., Grap, M. J., Younger, J. B., Ameringer, S., & Elswick, R. K. (2013) · Heart & Lung · doi:10.1016/j.hrtlng.2013.07.008 · Cited by 35
The Correct Position of the Head and Neck for Rapid Sequence Induction
Tran, D. O. (1987) · Anesthesiology · doi:10.1097/00000542-198711000-00053 · Cited by 34
Anxiety or depression during withdrawal of hypnotic treatments
LADER, M. H. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90142-2 · Cited by 33
LADER, M. H., & Lawson, C. (1987) · Clinical Neuropharmacology · doi:10.1097/00002826-198708000-00001 · Cited by 33
(2006) · PubMed · Cited by 33
Tsutsui, S., & Zolpidem Study Group (2001) · Journal of International Medical Research · doi:10.1177/147323000102900303 · Cited by 32
Changing antipsychotic medication: guidelines on the transition to treatment with Risperidone
Borison, R. L. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80211-6 · Cited by 32
Lemesle, F., Lemesle, F., Nicola, W., & Jonville‐Béra, A. ‐. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.07.007 · Cited by 31
Evaluation and treatment of ADHD.
Smucker, W. D., & Hedayat, M. (2001) · PubMed · Cited by 31
Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis
Gündüz, T., Kürtüncü, M., & Eraksoy, M. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.11.003 · Cited by 30
CLINICAL CONTRIBUTION TO DRUG ADDICTION: THE STRUGGLE FOR CURE AND THE CONSCIOUS REASONS FOR RELAPSE
Kolb, L. C. (1927) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-192707000-00003 · Cited by 29
Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation
Schultz, S. K., Miller, D. D., Arndt, S., Ziebell, S., Gupta, S., & Andreasen, N. C. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00082-8 · Cited by 29
Clomipramine concentration and withdrawal symptoms in 10 neonates
ter Horst, P. G. J., van der Linde, S., Smit, J. P., den Boon, J., van Lingen, R. A., Jansman, F. G. A., De Jong‐van den Berg, L. T. W., & Wilffert, B. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04072.x · Cited by 29
Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod
Członkowska, A., Smoliński, Ł., & Litwin, T. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.01.006 · Cited by 29
Anxiolytics and sedative/hypnotics dependence
Busto, U. E., & Sellers, E. M. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01760.x · Cited by 28
Hamilton, K. R., Perry, M. E., Berger, S. S., & Grunberg, N. E. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq179 · Cited by 27
Ito, T., Shibata, K., Watanabe, A., & Akabane, J. (2001) · European Journal of Pediatrics · doi:10.1007/s004310100743 · Cited by 25
Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation
Roehrs, T., Merlotti, L., Zorick, F., & Roth, T. (1992) · Psychopharmacology · doi:10.1007/bf02245287 · Cited by 25
Gender Differences in Diazepam Withdrawal Syndrome in Mice
Pesce, M. E., Acevedo, X., Pinardi, G., & Miranda, H. F. (1994) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1994.tb00374.x · Cited by 25
Dopamine agonists and neuroleptic malignant syndrome
Rosse, R. B., & Ciolino, C. P. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.2.270b · Cited by 24
Zolpidem-related epileptic seizures: a case report
Tripodianakis, J., Potagas, C. M., Papageorgiou, P., Lazaridou, M., & Matikas, N. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00031-2 · Cited by 21
Benzodiazepine dependence, withdrawal severity, and clinical outcome: effects of personality.
Rickels, K., Schweizer, E. E., Case, G. W., & España, F. G. (1988) · PubMed · Cited by 21
Takotsubo Cardiomyopathy Due to Iatrogenic Methadone Withdrawal
Saiful, F. B., Lafferty, J., Jun, C. H., Teli, S., Duvvuri, S., Khattri, S., & Bhat, T. (2011) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0600 · Cited by 20
[Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids].
Medraś, M., & Tworowska, U. (2001) · PubMed · Cited by 20
Clomipramine withdrawal in newborns
Bloem, B. R., Lammers, G. J., Roofthooft, D. W. E., de Beaufort, A. J., & Brouwer, O. F. (1999) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.81.1.f77a · Cited by 20
Rebound Phenomena: Results of a 10 Years’ (1970-1980) Literature Review
Lupolover, R., Dazzi, H., & Ward, J. (2017) · International Pharmacopsychiatry · doi:10.1159/000468579 · Cited by 19
Withdrawal-Emergent Dyskinesia and Supersensitivity Psychosis Due to Olanzapine Use
Karaş, H., Güdük, M., & Saatçioğlu, Ö. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.10122 · Cited by 19
High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review
Shukla, L., Chattopadhyay, A., Kandasamy, A., & Benegal, V. (2016) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_80_14 · Cited by 19
Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008.
Koren, G., & Boucher, N. (2009) · PubMed · Cited by 18
Neuroleptic malignant syndrome: When levodopa withdrawal is the cause
Rainer, C., Scheinost, N. A., & Lefeber, E. J. (1991) · Postgraduate Medicine · doi:10.1080/00325481.1991.11700900 · Cited by 18
Neuroleptic malignant syndrome. amitriptyline, and thioridazine
Corrigan, F. M., & Coulter, F. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90044-3 · Cited by 18
Management of Zolpidem Withdrawal
Watsky, E. J. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199612000-00010 · Cited by 18
Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults
Reeves, R. R., & Kamal, A. H. (2019) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2019.055 · Cited by 18
Antidepressant withdrawal: prospective findings
Ceccherini‐Nelli, A., Bardellini, L., Cur, A., Guazzelli, M., Maggini, C., & Dilsaver, S. C. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.1.165a · Cited by 14
Rebound Psychoses following the Discontinuation of a High Potency Neuroleptic
Kahne, G. J. (1989) · The Canadian Journal of Psychiatry · doi:10.1177/070674378903400312 · Cited by 14
Brantley, E. J., Cohn, J. V., & Babu, K. M. (2009) · Journal of Medical Toxicology · doi:10.1007/bf03161096 · Cited by 13
Alleviating Symptoms of Withdrawal from an Opioid
Wakim, J. H. (2012) · Pain and Therapy · doi:10.1007/s40122-012-0004-5 · Cited by 12
A review of recent literature on barbiturate addiction and withdrawal.
Gault, F. P. (1976) · PubMed · Cited by 9
Psychostimulant withdrawal and detoxification
Jenner, L., & Saunders, J. B. (2004) · Cited by 8
The Pharmacodynamics of PK 11195 in Diazepam-Dependent Male and Female Rats
Sloan, J. W., Wala, E. P., Jing, X., & Holtman, J. R. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00239-2 · Cited by 8
Recurrent Benzodiazepine Withdrawal Catatonia in an Older Adult
Lebin, L. G., & Cerimele, J. M. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060637 · Cited by 8
Delayed Onset of Neuroleptic Malignant Syndrome after Discontinuation of Thioridazine
Kasckow, J., Dolor, R. J., & Lipper, S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199004000-00027 · Cited by 7
Chartier, K. G., Sanchez, K., Killeen, T. K., Burrow, A., Carmody, T. J., Greer, T. L., & Trivedi, M. H. (2015) · American Journal on Addictions · doi:10.1111/ajad.12190 · Cited by 7
XIV. Addiction to barbiturate and nonbarbiturate sedative drugs.
Essig, C. F. (1968) · PubMed · Cited by 6
Research works printed but not linked: 3
- 2013, Diagnostic and statistical manual of mental disorders, 5th Edition: DSM-5
- Himmelsbach, 1939, Studies of certain addiction characteristics of (a) dihydromorphine (“Paramorphan”); (b) dihydrodesoxymorphineD (“Desomorphine”); (c) dihydrodesoxycodeine (“Desocodeine”) and (d) methyldihydromorphinone (“Metopon”), Pharmacol Exp Ther, 67, 239
- 2008, Ministry of Health NG, AU
Cited by
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Clinical management of cannabis withdrawal
Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 135
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
“Therefore, “For drugs not associated with abuse potential, an individual may still develop dependence; but again, this would not be classified as an addiction” [21].”
BackgroundHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Metadata
- Authors
- Lerner, A., & Klein, M.
- Affiliations
- United States Food and Drug Administration (US)
- Controlled Substance Scientific Solutions LLC, 4601 North Park Avenue #506, Chevy Chase, MD 20815-4572, USA
- Corresponding author
- Lerner, Alicja
- Klein, Michael
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-01
- Volume
- 1
- Issue
- 1
- Pages
- fcz025-fcz025
- ISSN
- 2632-1297 (ISSN-L)
- PMC
- PMC7425303
- OpenAlex
- W2980350741
- Semantic Scholar
- 89034519e35d0ae0d84d1831e16309eaa7352028
- Cited by
- 89
- References
- 200
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 16 · 2023: 17 · 2022: 11 · 2021: 12 · 2020: 6
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Brain Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Oak Ridge Institute for Science and Education
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- drug addiction, drug withdrawal, rebound, central nervous system drugs, withdrawal syndrome, addiction, substance use disorders, Controlled Substances Act, drug scheduling, new drug development, clinical trial design, drug safety assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.